Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) announced Thursday that elinzanetant, its experimental therapy for hot flashes, reached the ...

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

This article reviews the published literature on the use of venlafaxine, fluoxetine, and paroxetine for the treatment of hot flashes.

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

As US Surgeon General Dr. Vivek Murthy nears the end of his second term as the nation’s doctor, a final diagnosis of his ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

produced basic summary statistics for hot flash scores and frequency from raw individual patient data pooled from all 10 studies, which included information on individual patient treatment ...

Hepatic function should be evaluated prior to initiating treatment with Veozah. The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk ...

Veozah is an oral, neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The labeling for the product now includes a boxed warning ...